Summarized by Masters of Longevity from PR Newswire.
A biotech partnership announcement describing an agreement to license a next-generation blood–brain barrier–crossing AAV capsid for a gene therapy program targeting Friedreich ataxia, previewing a technical development and collaborative research effort readers can explore.
Key Takeaways
- Apertura Gene Therapy granted Lexeo Therapeutics access to its TfR1 CapX capsid for an FA program.
- TfR1 CapX is an intravenously delivered capsid designed to target hTfR1 and cross the blood-brain barrier.
- Apertura has licensed its next-generation capsids to multiple partners and expects several programs to enter clinical trials within 12 months.
